Bearish Chart Formation for Catalyst Biosciences, Inc. (CBIO) After Forming Multiple Bottom Chart Pattern

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Logo

The stock of Catalyst Biosciences, Inc. (CBIO) shows a multiple bottoms pattern with $10.25 target or 4.00 % below today’s $10.68 share price. The 5 months chart pattern indicates high risk for the $127.55 million company. It was reported on Dec, 2 by Finviz.com. If the $10.25 price target is reached, the company will be worth $5.10 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 1.23% or $0.13 during the last trading session, reaching $10.68. About 154,957 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has risen 166.85% since December 2, 2017 and is uptrending. It has outperformed by 151.23% the S&P500.

More notable recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: Seekingalpha.com which released: “Catalyst Bio down 33% premarket on appearance of neutralizing Abs to CB 2679d/ISU304 in hemophilia B study – Seeking Alpha” on June 18, 2018, also Marketwatch.com with their article: “STRO Stock Price – Sutro Biopharma Inc. Stock Quote (US: Nasdaq) – MarketWatch” published on September 03, 2018, Globenewswire.com published: “Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors – GlobeNewswire” on October 26, 2017. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) were released by: Seekingalpha.com and their article: “Your Daily Pharma Scoop: Catalyst Bio Succeeds, CTI Moves Forward, Pfizer Positive – Seeking Alpha” published on July 20, 2018 as well as Benzinga.com‘s news article titled: “Catalyst Biosciences (NASDAQ:CBIO) Shares Volatile On Positive Late-Stage Hemophilia Trial Results – Benzinga” with publication date: July 18, 2018.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $127.55 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.